skip navigation

Skip Nav

AIDSinfo Drug Database

AIDSinfo Drug Database

Drugs by class

FDA-approved

Investigational

Rintatolimod  Audio icon

Other Names: AMP, Ampligen, Atvogen, poly(I:C12U), polyI:polyC12U, poly(I)-poly(C12U)
Drug Class: Biological Response Modifiers
Molecular Formula: (C10 H13 N4 O8 P)x.(C9 H14 N3 O8 P.C9 H13 N2 O9 P)x
Registry Number: 38640-92-5 (CAS)
Chemical Name: IIIIIIIIIIIIICCCCCCCCCCCCU
Chemical Class: Oligonucleotides
Company: Hemispherx; Rega Institute For Medical Research
Phase of Development: Phase II
(Compound details obtained from ChemIDplus Advanced1 and NIAID Therapeutics Database2)

What is an investigational drug?

An investigational drug is one that is under study and is not approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.

What is rintatolimod?

Rintatolimod is an investigational drug that is categorized as a biological response modifier.2 Biological response modifiers (also called immunomodulators) are substances that help to activate, boost, or restore normal immune function.3,4

Rintatolimod was studied for its ability to delay re-emergence of HIV during structured treatment interruptions of antiretroviral therapy (ART). A structured treatment interruption is a planned break from treatment, for example, ART. Structured interruption of ART is not recommended outside of controlled clinical trials.5,6
 
Rintatolimod was also studied as a medicine to add to ART in people whose current HIV medicines weren’t controlling their HIV infection.7 Also, rintatolimod has been studied for various non-HIV-related uses, including to treat chronic fatigue syndrome and cancer and to boost the body’s immune response to a flu vaccine.8-11 

How are clinical trials of investigational drugs conducted?

Clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions.12

  • Phase I trials: Researchers test an investigational drug in a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects.
  • Phase II trials: The investigational drug is administered to a larger group of people (100–300) to determine its effectiveness and to further evaluate its safety.
  • Phase III trials: The investigational drug is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational drug to be used safely.12

In most cases, an investigational drug must be proven safe and effective in a Phase III clinical trial to be considered for approval by FDA for sale in the United States. Some drugs go through FDA’s accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug’s risks, benefits, and optimal use.12

In what phase of testing is rintatolimod?

Rintatolimod for HIV treatment has been studied in Phase II clinical trials.2

What have recent studies shown about rintatolimod?

A Phase II study looked at whether rintatolimod could extend the time a person could stay off HIV medicines during structured interruptions of ART before their HIV began to rebound. (A rebound is when there are detectable levels of HIV in the blood after a period of undetectable levels.) During this study, up to three structured interruptions of ART were planned over a 64-week period. All participants in this study had taken HIV medicines before entering the study (treatment-experienced) and had a viral load level (the amount of HIV in the blood) of less than 50 copies/mL while on ART. The participants were divided into two groups. One group received rintatolimod by intravenous injection twice weekly during the structured interruptions of ART. In the other group (the control group), the participants did not receive rintatolimod during the structured interruptions of ART. The structured interruptions of ART were stopped once a participant’s viral load rose to certain detectable levels.5,6

In this study, participants receiving rintatolimod were able to stay off HIV medicines for longer (while maintaining controlled viral load levels) during the initial structured interruption of ART than participants in the control group. The average duration of the first structured treatment interruption in participants receiving rintatolimod was 27 weeks, whereas it was 13 weeks for participants in the control group. CD8 T lymphocytes (a type of immune cell that recognizes and destroys cells infected with microorganisms, such as bacteria or virus) increased more in participants receiving rintatolimod than in participants in the control group. In terms of safety, side effects with use of rintatolimod were described as being generally mild.6

Rintatolimod was also studied in a Phase II trial as a medicine to add to ART in people whose HIV medicines weren’t controlling their HIV infection. This study, however, was stopped prior to completion.7 

What side effects might rintatolimod cause?

In the Phase II study looking at the use of rintatolimod during structured interruptions of ART, side effects were generally mild and cleared up without treatment.6 

Because rintatolimod is still being studied, information on possible side effects of the drug is not complete. As testing of rintatolimod continues, additional information on possible side effects will be gathered.

Where can I get more information about clinical trials studying rintatolimod?

More information about rintatolimod-related research studies is available from the AIDSinfo database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.

I am interested in participating in a clinical trial of rintatolimod. How can I find more information about participating in a clinical trial?

Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.12

Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.

References

  1. United States National Library of Medicine. ChemIDplus Advanced. Last accessed on April 16, 2014.
  2. National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Last accessed on April 16, 2014.
  3. AIDS Clinical Trials Group (ACTG) Network website. Glossary of HIV-Related Terms. Definition for Biological Response Modifier (BRM). Last accessed on April 16, 2014.
  4. HealthHIV website. HIV Glossary of Terms. Definition for Biological Response Modifier (BRM). Last accessed on April 16, 2014.
  5. Hemispherx Biopharma. The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 6, 2002. NLM Identifier: NCT00035893. Last accessed on April 16, 2014.
  6. Blick G, Greiger-Zanlungo P, Strayer DR, Mitchell WM, Carter WA. Interim Results of AMP720: A Phase IIb Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Ampligen (Poly I:Poly C12U) Against HIV During STI. 2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 596. Last accessed on April 16, 2014.
  7. Hemispherx Biopharma. A Multi-Center, Randomized, Controlled Study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 3, 2002. NLM Identifier: NCT00035581. Last accessed on April 16, 2014.
  8. Strayer DR, Carter WA, Stouch BC, et al. A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome. PLoS One. 2012;7(3):e31334. Last accessed on April 16, 2014.
  9. University of Washington. Phase I-II Study of HER2 Vaccination With Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 16, 2011. NLM Identifier: NCT01355393. Last accessed on April 16, 2014.
  10. Pawel Kalinski. Randomized Phase I/II Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 29, 2012. NLM Identifier: NCT01545141. Last accessed on April 16, 2014.
  11. Hemispherx Biopharma. A Phase I/II, Two-Staged, Single-Center, Randomized, Double-Blind, Antibody Titer Study to Assess Immunogenicity and Safety of FluMist® Intranasal Influenza Vaccine Administered With and Without a TLR-3 Agonist, Ampligen®. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 2, 2012. NLM Identifier: NCT01591473. Last accessed on April 16, 2014.
  12. National Institutes of Health (NIH). NIH Clinical Research Trials and You. Last accessed on April 16, 2014.


Last Reviewed: April 16, 2014

Last Updated: April 25, 2014


Back to Top